Skip to main content

Table 4 Number of positive cases by each biomarker in peripheral blood

From: Diagnostic utility of LunXmRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer

Group

Total number

Positive Detection Rate

  

LunX

CK19

CEA

VEGF-C

hnRNP A2/B1

NSCLC

44

33/44 (75.0%)

37/44 (84.1%)

11/44 (25.0%)

37/44 (84.1%)

44/44 (100%)

Other epithelial cancer

28

0/28 (0%)

19/28 (67.9%)

13/28 (46.4%)

26/28 (92.9%)

28/28 (100%)

Pneumonia

10

0/10 (0%)

0/10 (0%)

0/10 (0%)

8/10 (80.0%)

10/10 (100%)

Healthy

15

0/15 (0%)

0/15 (0%)

0/15 (0%)

10/15 (66.7%)

15/15 (100%)

P value

< 0.001*

< 0.001*

0.002*

0.174*

-

  

< 0.001#

0.106#

0.060#

-

-

  

/

0.290$

< 0.001$

-

-

  1. For each gene marker, when the copy number was less than 100, it could not be detectable as a negative case using our established real-time PCR assay. The positive detection rate was calculated by the number of positive cases/total number. * represented the analysis among NSCLC, other epithelial cancer, pneumonia and healthy groups for each biomarker. # represented the analysis between NSCLC and other epithelial cancer groups for each biomarker. $ represented the analysis between the biomarker and LunX for NSCLC. P values were calculated using χ2 test.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us